Revisiting Fulvestrant Dosing in Uncertain Economic Times.
作者信息
Patel Amol, Gupta Vineet Govinda, Biswas Bivas, Das Chandan K, Batra Atul, Ganguly Sandip, Bhethanabhotla Sainath
机构信息
Army Hospital Research & Referral, New Delhi, India.
Department of Medical Oncology, Artemis Hospitals, Gurugram, India.
出版信息
JCO Glob Oncol. 2021 Jan;7:1-3. doi: 10.1200/GO.20.00362.
Abstract
摘要
相似文献
1
Revisiting Fulvestrant Dosing in Uncertain Economic Times.在经济形势不明朗时期重新审视氟维司群的给药方案。
JCO Glob Oncol. 2021 Jan;7:1-3. doi: 10.1200/GO.20.00362.
2
RE: Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial.
J Natl Cancer Inst. 2017 Mar 1;109(3):1. doi: 10.1093/jnci/djw234.
3
Fulvestrant-Big Mac Index: Defining Inequality in Oncology.
JCO Glob Oncol. 2021 Apr;7:646-647. doi: 10.1200/GO.21.00047.
4
Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader.药效学成像指导选择性雌激素受体降解剂的给药。
Clin Cancer Res. 2015 Mar 15;21(6):1340-7. doi: 10.1158/1078-0432.CCR-14-1178. Epub 2015 Jan 21.
5
Fulvestrant for Untreated Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.氟维司群治疗未经治疗的激素受体阳性局部晚期或转移性乳腺癌：一项 NICE 单技术评估的证据审查组观点。
Pharmacoeconomics. 2019 Jun;37(6):753-762. doi: 10.1007/s40273-018-0725-3.
6
The history and mechanism of action of fulvestrant.氟维司群的历史及作用机制。
Clin Breast Cancer. 2005 Apr;6 Suppl 1:S5-8. doi: 10.3816/cbc.2005.s.008.
7
The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.氟维司群在激素受体阳性乳腺癌患者管理中的治疗作用。
Breast. 2014 Jun;23(3):201-8. doi: 10.1016/j.breast.2014.01.016. Epub 2014 Mar 1.
8
A role for fulvestrant monotherapy in the first-line treatment of ER+ metastatic breast cancer?氟维司群单药疗法在雌激素受体阳性转移性乳腺癌一线治疗中是否有作用？
Breast J. 2020 Feb;26(2):109-111. doi: 10.1111/tbj.13495. Epub 2019 Sep 20.
9
Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer.氟维司群：一种用于治疗晚期乳腺癌的新型雌激素受体拮抗剂。
Drugs Today (Barc). 2004 Sep;40(9):751-64. doi: 10.1358/dot.2004.40.9.850495.
10
Fulvestrant: an estrogen receptor antagonist that downregulates the estrogen receptor.氟维司群：一种下调雌激素受体的雌激素受体拮抗剂。
Semin Oncol. 2003 Oct;30(5 Suppl 16):14-20. doi: 10.1053/j.seminoncol.2003.08.003.
本文引用的文献
1
Country-specific nutrient requirements & recommended dietary allowances for Indians: Current status & future directions.印度特有的营养需求与推荐膳食供给量：现状与未来方向。
Indian J Med Res. 2018 Nov;148(5):522-530. doi: 10.4103/ijmr.IJMR_1762_18.
2
Quantifying the financial burden of households' out-of-pocket payments on medicines in India: a repeated cross-sectional analysis of National Sample Survey data, 1994-2014.量化印度家庭药品自付费用的经济负担：1994-2014 年全国抽样调查数据的重复横断面分析。
BMJ Open. 2018 May 31;8(5):e018020. doi: 10.1136/bmjopen-2017-018020.
3
Economic burden of cancer in India: Evidence from cross-sectional nationally representative household survey, 2014.印度癌症的经济负担：基于 2014 年全国代表性家庭横断面调查的证据。
PLoS One. 2018 Feb 26;13(2):e0193320. doi: 10.1371/journal.pone.0193320. eCollection 2018.
4
Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China.500毫克与250毫克氟维司群用于雌激素受体阳性晚期乳腺癌绝经后女性：一项在中国进行的随机、双盲注册试验
Oncotarget. 2016 Aug 30;7(35):57301-57309. doi: 10.18632/oncotarget.10254.
5
Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.激素受体阳性转移性乳腺癌的内分泌治疗：美国临床肿瘤学会指南。
J Clin Oncol. 2016 Sep 1;34(25):3069-103. doi: 10.1200/JCO.2016.67.1487. Epub 2016 May 23.
6
Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.随机对照 CONFIRM 试验：氟维司群 500mg 与 250mg 的最终总生存比较。
J Natl Cancer Inst. 2014 Jan;106(1):djt337. doi: 10.1093/jnci/djt337. Epub 2013 Dec 7.
7
Cost-effectiveness of fulvestrant 250 mg versus 500 mg in postmenopausal women with estrogen receptor-positive metastatic breast cancer and disease progression after antiestrogen therapy.250毫克与500毫克氟维司群在雌激素受体阳性转移性乳腺癌且抗雌激素治疗后疾病进展的绝经后女性中的成本效益。
J Oncol Pharm Pract. 2012 Dec;18(4):394-401. doi: 10.1177/1078155212438253. Epub 2012 Feb 22.
8
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study.氟维司群新辅助内分泌治疗中生物标志物的剂量依赖性变化：来自随机 II 期研究 NEWEST 的结果。
Breast Cancer Res Treat. 2012 May;133(1):237-46. doi: 10.1007/s10549-011-1947-7.
9
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.CONFIRM 三期临床试验结果：比较氟维司群 250mg 与氟维司群 500mg 在绝经后雌激素受体阳性的晚期乳腺癌女性中的疗效。
J Clin Oncol. 2010 Oct 20;28(30):4594-600. doi: 10.1200/JCO.2010.28.8415. Epub 2010 Sep 20.
10
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).FINDER2 研究：比较三种剂量氟维司群治疗绝经后晚期乳腺癌的 II 期临床研究结果
Breast Cancer Res Treat. 2010 Sep;123(2):453-61. doi: 10.1007/s10549-010-1022-9. Epub 2010 Jul 15.
Zotero 插件